Cody Parsons, APh, PharmD, BCCCP, says protected pharmacist access lets patients with heart failure be seen more often than typical clinic visits allow.
|Videos|June 18, 2015
Guidelines for Drug Product Naming
Michael Cohen, RPh, MS, ScD, DPS, FASHP, President of the Institute for Safe Medicine Practices (ISMP), discusses the guidelines in place to avoid having drug products with similar names. He also discusses instances in which product names have been the source for error.
Advertisement
Michael Cohen, RPh, MS, ScD, DPS, FASHP, President of the Institute for Safe Medicine Practices (ISMP), discusses the guidelines in place to avoid having drug products with similar names. He also discusses instances in which product names have been the source for error.
This video was shot at ASHP's Summer Meetings and Exposition in Denver in June 2015.
Advertisement
Related to this article
The evidence for GLP-1 receptor agonists keeps growing, while access for low-income patients keeps narrowing.
Specialty pharmacists can help patients with cancer weigh the benefits and risks of GLP-1 receptor agonists as use expands and new evidence emerges.
Pharmacists can work alongside dermatologists, nurses, and other health care professionals to help answer skin care–related questions and help patients understand trial outcomes.
Early metformin may curb insulin starts in gestational diabetes, while a separate analysis ties a history of the condition to advanced CKM syndrome.
Pharmacy Times previews enlicitide, survodutide, diet and heart failure risk, and pharmacist-led HF care ahead of the AHA Scientific Sessions in Chicago.
Expected in the first half of 2028, the planned separation would create a stand-alone retail pharmacy company with nearly 30,000 pharmacists.
RSV hospitalization raised short-term invasive pneumococcal disease risk, especially among unvaccinated individuals.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Understanding Kratom: Pharmacology, Safety, and Regulation
2
How Stanford Pharmacists Help Close Heart Failure Therapy Gaps
3
GLP-1 Receptor Agonists and Cancer: Considerations for Specialty Pharmacists
4
GLP-1s and Obesity Care: Cardiorenal Outcomes, Prescribing Considerations, and Access Barriers
5